Major Clinical Trial Success Boosts AstraZeneca Heart Drug

AstraZeneca's  blood-thinning drug Brilinta cut the risk of death or heart attack in patients with a history of previous attacks, according to a major clinical trial that will boost hopes for the closely watched product. Giving Brilinta to patients who had a heart attack over a year ago could more than double the number of people eligible for the medicine, which the company has predicted could eventually generate sales of $3.5 billion a year. Results from the 21,000-patient...

© La Voix de l'Amérique - mercredi 14 janvier 2015